Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers

Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial...

Descrición completa

Detalles Bibliográficos

Principais autores:	Oliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, Wolfgang Kristoferitsch, Jürgen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2021-03-01
Series:	Biomolecules
Assuntos:	multiple sclerosis fatigue glatiramer acetate
Acceso en liña:	https://www.mdpi.com/2218-273X/11/3/393
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!